Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inpegsomatropin in Children With Idiopathic Short Stature
NCT06927310Phase 3Recruiting
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of genotropin miniquick in Idiopathic Short Stature (ISS) (2 arms), sponsored by Xiamen Tebao Biological Engineering Co., Ltd. Primary endpoint: Growth velocity at 52 weeks. Started Apr 2025; status: recruiting.
02
Drugs
genotropin miniquick
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NCT06927310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06927310.